Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 52
Filter
1.
Acta Paediatr ; 93(11): 1456-62, 2004 Nov.
Article in English | MEDLINE | ID: mdl-15513572

ABSTRACT

BACKGROUND: Girls adopted from developing countries often have early or precocious puberty, requiring treatment with gonadotrophin-releasing hormone (GnRH) analogues. During such treatment, decreased growth velocity is frequent. AIM: To study whether the addition of growth hormone (GH) to GnRH analogue treatment improves final height in girls with early or precocious puberty. METHODS: Forty-six girls with early or precocious puberty (age < or =9.5 y) adopted from developing countries were randomized for treatment for 2-4 y with GnRH analogue, or with a combination of GH and GnRH analogue. RESULTS: During treatment, the mean growth velocity in the GH/GnRH analogue group was significantly higher compared to the control group. Combined GH/GnRH analogue treatment resulted in a higher final height: 158.9 cm compared to 155.8 cm in the GnRH analogue-treated group. Three out of 24 girls (13%) in the combined group and nine of the 22 girls (41%) treated with GnRH analogue alone attained a final height below -2 standard deviation scores (SDS). CONCLUSION: The difference between the two groups is statistically significant, and possibly of clinical importance. A future challenge is to identify a subgroup with clinically significant advantage of GH addition to GnRH analogue treatment. Being very short on arrival in Sweden and being short and young at start of treatment are possible indicators.


Subject(s)
Adoption , Body Height , Buserelin/therapeutic use , Developing Countries , Growth Hormone/therapeutic use , Puberty, Precocious/physiopathology , Child , Female , Humans , Puberty/physiology
2.
J Pediatr ; 135(6): 739-45, 1999 Dec.
Article in English | MEDLINE | ID: mdl-10586178

ABSTRACT

OBJECTIVE: To study patients with autosomal recessive pseudohypoaldosteronism type 1 and to relate pulmonary disease to gene mutations of the epithelial sodium channel (ENaC). STUDY DESIGN: Clinical and laboratory data were collected from 4 Swedish patients with pseudohypoaldosteronism type 1. The genes for ENaC and cystic fibrosis transmembrane conductance regulator were analyzed for mutations with methods including DNA sequencing. RESULTS: Three novel mutations were found in the alpha-gene of ENaC, 2 frameshifts (1449delC and 729delA) and 1 missense mutation resulting in the substitution of leucine for serine 562 in the alpha-chain (S562L). The 1449delC mutation was found in all patients in either homozygous or heterozygous form and seems to be the predominant cause of pseudohypoaldosteronism in Sweden. The allele coding for S562L also contained a transition converting tryptophan 493 to arginine (W493R), which seems to be a rare polymorphism. All patients had pulmonary symptoms to various degrees. The bacterial findings resembled, to some extent, those in cystic fibrosis, but development of chronic lung disease and progressive decline in lung function were not observed. CONCLUSIONS: Genetic deficiencies of the alpha subunit of the ENaC are associated with prominent lung symptoms, which are, however, clearly different from those in cystic fibrosis.


Subject(s)
Lung Diseases/genetics , Pseudohypoaldosteronism/genetics , Sodium Channels/deficiency , Child, Preschool , Epithelium , Female , Humans , Lung Diseases/etiology , Mutation , Polymorphism, Single-Stranded Conformational , Pseudohypoaldosteronism/complications , Sequence Analysis, DNA , Sodium Channels/genetics
3.
Acta Paediatr ; 88(9): 933-6, 1999 Sep.
Article in English | MEDLINE | ID: mdl-10519331

ABSTRACT

This study was undertaken to investigate the prevalence of coeliac disease in children and adolescents with Turner syndrome. Eighty-seven children and adolescents with Turner syndrome were screened for IgA-antiendomysium antibodies (EMA) and IgA-antigliadin antibodies (AGA), 5% (4/87) being found to be EMA-positive, and 15% (13/87) to have AGA levels above normal. Of the 10 patients who were either AGA- or EMA-positive and further investigated with intestinal biopsy, four manifested villous atrophy (i.e. all three of the EMA-positive patients, but only one of the seven AGA-positive patients). The results suggest EMA-positivity to be a good immunological marker for use in screening for coeliac disease, and such screening to be justified in patients with Turner syndrome.


Subject(s)
Antibodies, Anti-Idiotypic/blood , Celiac Disease/complications , Celiac Disease/epidemiology , Immunoglobulin A , Turner Syndrome/complications , Adolescent , Case-Control Studies , Celiac Disease/blood , Child , Enzyme-Linked Immunosorbent Assay , Female , Gliadin/immunology , Humans , Prevalence , Sweden/epidemiology
4.
Acta Paediatr Suppl ; 88(428): 80-4, 1999 Feb.
Article in English | MEDLINE | ID: mdl-10102059

ABSTRACT

This paper reports results from an ongoing, randomized, multicentre national trial. The aim is to elucidate whether a dose of growth hormone (GH) of 0.2 IU/kg (0.07 mg/kg), given either as once-daily or twice-daily injections during puberty, is more effective than a once-daily dose of 0.1 IU/kg/day (0.03 mg/kg/day) in improving final height in children with GH deficiency (GHD). The twice-daily regimen comes closer to the spontaneous GH secretion pattern in puberty. Ninety-two children with GHD who had been receiving GH therapy for at least 1 year, and with spontaneous puberty or who were prepubertal and due to be started on replacement therapy to induce puberty, were randomly assigned to receive GH as follows: group A, 0.1 IU/kg/day (0.03 mg/kg/day), administered once daily; group B, 0.2 IU/kg/day (0.07 mg/kg/day), administered once daily; and group C, 0.2 IU/kg/day (0.07 mg/kg/day), divided into two equal injections given at 12-hour intervals. Pubertal height gain was 0.7, 0.7 and 1.3 SDS for groups A, B and C, respectively. The gain in height during puberty was thus most marked in group C. Mean final height, when corrected for parental height, was between 0 and 1 SDS in all treatment groups. All but seven children reached a final height within +/- 2 SD of the general population. There was a wide range of final heights in all three treatment groups. This variation in response suggests the need to individualize treatment in order to achieve an appropriate final height for most individuals.


Subject(s)
Body Height/drug effects , Growth Disorders/drug therapy , Human Growth Hormone/administration & dosage , Human Growth Hormone/deficiency , Adolescent , Child , Dose-Response Relationship, Drug , Drug Administration Schedule , Female , Follow-Up Studies , Growth Disorders/etiology , Humans , Male , Puberty/physiology , Sweden , Treatment Outcome
5.
J Pediatr Endocrinol Metab ; 9(2): 201-4, 1996.
Article in English | MEDLINE | ID: mdl-8887145

ABSTRACT

Five children with dyschondrosteosis (Léri-Weill syndrome) were found to have insufficient growth hormone (GH) secretion and were treated with GH. After one year of treatment height velocity SDS as well as height SDS increased significantly. In three children who had completed their second year of treatment, the increase in height velocity was sustained and for all patients predicted adult height increased during the GH treatment.


Subject(s)
Human Growth Hormone/therapeutic use , Osteochondrodysplasias/drug therapy , Adolescent , Arginine , Body Height , Body Weight , Child , Female , Human Growth Hormone/metabolism , Humans , Insulin , Male , Osteochondrodysplasias/physiopathology , Syndrome
6.
J Clin Endocrinol Metab ; 81(2): 635-40, 1996 Feb.
Article in English | MEDLINE | ID: mdl-8636281

ABSTRACT

The spontaneous growth process in Turner's syndrome is characterized by a progressive decline in height velocity during childhood and no pubertal growth spurt. Therefore, therapy aimed at improving height during childhood as well as increasing final height is desirable for most girls with Turner's syndrome. Forty-five girls with Turner's syndrome, 9-16 yr of age (mean age, 12.2 yr), were allocated to three study groups. Group 1 (n = 13) was initially treated with oxandrolone alone; after 1 yr of treatment, GH without (group 1a; n = 6) or with (group 1b; n = 7) ethinyl estradiol was added. Group 2 (n = 17) was treated with GH plus oxandrolone. Group 3 (n = 15) was treated with GH, oxandrolone, and ethinyl estradiol. The dosage were: GH, 0.1 IU/kg.day; oxandrolone, 0.05 mg/kg.day; and ethinyl estradiol, 100 ng/kg.day. A height of 150 cm or more was achieved in 61%, 75%, and 60% of the girls in groups 1, 2, and 3, respectively. The most impressive increase in height was seen in group 2. In this group the mean final height was 154.2 cm (SD = 6.6), which is equivalent to a mean net gain of 8.5 cm (SD = 4.6) over the projected final height. In group 3, in which ethinyl estradiol was included from the start of therapy, the initially good height velocity decelerated after 1-2 yr of treatment. Their mean final height was 151.1 (SD = 4.6) cm, equivalent to a mean net gain of 3.0 cm (SD = 3.8). A similar growth-decelerating effect of ethinyl estradiol was seen in group 1b. We conclude that in girls with Turner's syndrome who are older than 9 yr of age, treatment with GH in combination with oxandrolone results in significant growth acceleration, imitating that in normal puberty, leading to a more favorable height during childhood. This mode of treatment also results in a significantly increased final height, permitting a great number of the girls to attain a final height of more than 150 cm. However, early addition of estrogen decelerates the height velocity and reduces the gain in height.


Subject(s)
Anabolic Agents/therapeutic use , Body Height , Growth Hormone/therapeutic use , Oxandrolone/therapeutic use , Turner Syndrome/drug therapy , Adolescent , Age Determination by Skeleton , Child , Ethinyl Estradiol/therapeutic use , Female , Humans , Turner Syndrome/physiopathology
7.
Acta Paediatr ; 84(1): 63-5, 1995 Jan.
Article in English | MEDLINE | ID: mdl-7734902

ABSTRACT

The prevalence of thyroid autoantibodies, i.e. thyroglobulin antibodies and antibodies to thyroid peroxidase, was analyzed in 89 girls, aged 3-16 years (mean age 10 years), with Turner's syndrome. The analyses were performed before the start of growth-promoting treatment and during a follow-up period of 1-5 years. The patients were divided into four groups according to karyotype as follows: group 1, 45, X (n = 63); group 2 with structural abnormalities of the X chromosome (n = 10); group 3 with mosaicism but no structural abnormalities of the X chromosome (n = 10); and group 4, with isochromosome X of the long arm (n = 12): 199 healthy girls aged 12 years, served as controls. Thyroid autoantibodies were demonstrated in 46 of 89 (52%) patients with Turner's syndrome compared with 34 of 199 (17%) age-matched control girls (p < 0.001), thus confirming the relationship between thyroid abnormalities and Turner's syndrome. There was also an increase in the prevalence of thyroid antibodies with age. Simultaneous presence of both autoantibodies was significantly more frequent in group 1 (45, X) and group 4 (isochromosome X of the long arm) than in group 3 (mosaicism) (p = 0.04 and p < 0.002, respectively) and significantly more frequent in group 4 than in group 1 (p < 0.05). During 12-60 months of growth-promoting treatment, no increase in the prevalence of thyroid antibodies was observed. The findings demonstrate the importance of continuous monitoring of thyroid function in girls with Turner's syndrome.


Subject(s)
Autoantibodies/analysis , Growth Hormone/therapeutic use , Thyroid Gland/immunology , Turner Syndrome/immunology , Adolescent , Age Factors , Child , Child, Preschool , Female , Follow-Up Studies , Humans , Iodide Peroxidase/immunology , Karyotyping , Sweden , Thyroglobulin/immunology , Thyroid Gland/enzymology , Turner Syndrome/drug therapy , Turner Syndrome/genetics
8.
Acta Paediatr ; 83(1): 119-21, 1994 Jan.
Article in English | MEDLINE | ID: mdl-8193462

ABSTRACT

A six-year-old boy with severe intermittent diarrhoea was subjected to extensive diagnostic investigation and treatment before the administration of a laxative (sodium sulphate) by his mother was discovered. Early suspicion and analysis of faecal fluid for electrolytes and known laxative substances would have prevented the hazardous clinical course of this case.


Subject(s)
Diarrhea/etiology , Munchausen Syndrome by Proxy/diagnosis , Cathartics , Child , Chronic Disease , Humans , Male , Sulfates
9.
Diabet Med ; 10(6): 521-3, 1993 Jul.
Article in English | MEDLINE | ID: mdl-8395988

ABSTRACT

In a Swedish prospective study of congenital cytomegalovirus (CMV) infection, 76 infants were shown to be infected among 16,474 newborns screened by virus isolation in urine. Seventy-three of the excreters were followed up and one developed Type 1 diabetes, as compared to 38 of the 19,483 children born during the same period (p = 0.14, Fisher's one-tailed test). Thus we found no evidence that the combined finding of congenital CMV infection and Type 1 diabetes mellitus was related.


Subject(s)
Cytomegalovirus Infections/epidemiology , Diabetes Mellitus, Type 1/epidemiology , Autoantibodies/blood , C-Peptide/blood , Cytomegalovirus/isolation & purification , Cytomegalovirus Infections/congenital , Cytomegalovirus Infections/urine , Diabetes Mellitus, Type 1/blood , Diabetes Mellitus, Type 1/diagnosis , Follow-Up Studies , Glucagon , Glucose Tolerance Test , Humans , Infant, Newborn , Islets of Langerhans/immunology , Male , Prevalence , Sweden/epidemiology
10.
J Intern Med ; 233(3): 281-6, 1993 Mar.
Article in English | MEDLINE | ID: mdl-8450297

ABSTRACT

Two unrelated young males with the unusual simultaneous presence of insulin-dependent diabetes mellitus, ulcerative colitis and primary sclerosing cholangitis are reported. Both patients manifested homozygosity for the DR3-DQw2 (DQB*0201) HLA genotypes. We believe that homozygosity for this genotype may predispose for this type of multi-organ autoimmune disease.


Subject(s)
Cholangitis, Sclerosing/genetics , Colitis, Ulcerative/genetics , Diabetes Mellitus, Type 1/genetics , HLA-DQ Antigens/genetics , HLA-DR3 Antigen/genetics , Adolescent , Child , Cholangitis, Sclerosing/complications , Colitis, Ulcerative/complications , Diabetes Mellitus, Type 1/complications , Homozygote , Humans , Male
11.
Pediatr Res ; 32(6): 731-5, 1992 Dec.
Article in English | MEDLINE | ID: mdl-1287564

ABSTRACT

We report the finding of mitochondrial ATP-synthase deficiency in a child with persistent 3-methylglutaconic aciduria. The child presented in the neonatal period with severe lactic acidosis, which was controlled by Na-HCO3 and glucose infusions. During the 1st y of life, there were several episodes of lactic acidosis precipitated by infections or prolonged intervals between meals. The excretion of lactate in urine was variable, but there was a persistent high excretion of 3-methylglutaconic acid. The activity of 3-methylglutaconyl-CoA hydratase in fibroblasts was normal. The child had a hypertrophic cardiomyopathy and magnetic resonance images revealed hypoplasia of corpus callosum. The gross motor and mental development was retarded, but there were no other neurologic signs. Investigation of muscle mitochondrial function at 1 y of age revealed a severe mitochondrial ATP-synthase deficiency (oligomycin-sensitive, dinitrophenol-stimulated Mg2+ ATPase activity: 27 nmol x min-1 x (mg protein)-1, control range 223-673 nmol x min-1 x (mg protein)-1. The mitochondrial respiratory rate was low and tightly coupled. The respiratory rate was normalized by the addition of an uncoupler. Low Mg2+ ATPase activity was also demonstrated by histochemical methods. Morphologic examination revealed ultrastructural abnormalities of mitochondria. There was no deletion of mitochondrial DNA. The sequences of the ATP synthase subunit genes of mitochondrial DNA were in accordance with published normal sequences.


Subject(s)
Glutarates/urine , Mitochondria, Muscle/enzymology , Proton-Translocating ATPases/deficiency , Acidosis, Lactic/genetics , Acidosis, Lactic/metabolism , Cardiomyopathy, Hypertrophic/genetics , Cardiomyopathy, Hypertrophic/metabolism , Cardiomyopathy, Hypertrophic/pathology , DNA Mutational Analysis , DNA, Mitochondrial/genetics , Female , Humans , Infant , Metabolism, Inborn Errors/genetics , Metabolism, Inborn Errors/metabolism , Metabolism, Inborn Errors/pathology , Mitochondria, Muscle/pathology , Proton-Translocating ATPases/genetics
12.
Acta Paediatr ; 81(12): 1044-8, 1992 Dec.
Article in English | MEDLINE | ID: mdl-1363280

ABSTRACT

We report a case of Takayasu's disease with severe renovascular hypertension in a girl from Eritrea. In the "burn-out" phase after the erythrocyte sedimentation rate had normalized, reconstructive vascular surgery was performed as further progression of the disease seemed unlikely. However, probably due to her growth, the graft rotated and a second operation was successfully performed.


Subject(s)
Hypertension, Renovascular/etiology , Takayasu Arteritis/complications , Anastomosis, Surgical , Aortography , Blood Vessel Prosthesis , Child , Female , Humans , Hypertension, Renovascular/diagnostic imaging , Hypertension, Renovascular/surgery , Prognosis , Renal Artery/diagnostic imaging , Renal Artery/surgery , Takayasu Arteritis/diagnostic imaging , Takayasu Arteritis/surgery
13.
Acta Paediatr Scand ; 80(12): 1158-65, 1991 Dec.
Article in English | MEDLINE | ID: mdl-1785288

ABSTRACT

We describe spontaneous longitudinal growth in girls with Turner's syndrome (TS), using the infancy-childhood-puberty (ICP) growth model. Length/height during the first 12 years of life was studied in 58 Swedish girls with TS. Their mean length at birth was 47.8 cm (SDS -1.4) and mean height at 12.0 years of age 127.3 cm (SDS -3.0). A clear age-dependent subnormality was observed in the change in length-height SDS (delta SDS). Mean delta SDS values at ages 0.0 to 0.5 and 3.0 to 6.0 years were normal. In contrast, the mean delta SDS at ages 0.5 to 3.0 and 6.0 to 12.0 years were subnormal. The onset of the childhood growth component (normally located between 0.5 and 1.0 year of age) was, on the average, delayed by 0.28 year. This accounts for the subnormality of delta SDS at 0.5 to 3.0 years of age. About 50% of the variation in height at 12.0 years of age, as determined by a multiple linear regression analysis, was significantly explained by length at 0.5 year of age, age at the onset of the childhood component, and delta SDS at 6.0 to 12.0 years of age.


Subject(s)
Body Height , Growth Disorders/physiopathology , Linear Models , Models, Biological , Turner Syndrome/complications , Adolescent , Age Factors , Body Weight , Child , Child, Preschool , Cross-Sectional Studies , Female , Growth Disorders/epidemiology , Growth Disorders/etiology , Humans , Infant , Infant, Newborn , Longitudinal Studies , Predictive Value of Tests , Sweden/epidemiology
14.
Scand J Clin Lab Invest ; 51(5): 475-80, 1991 Sep.
Article in English | MEDLINE | ID: mdl-1947733

ABSTRACT

Sweat secretion rate (SSR) was measured by the pilocarpine iontophoresis test in (a) 254 healthy children and adolescents (aged 6.0 to 19.2 years, mean age 11.2 years); in (b) 58 healthy adults (aged 20.4 to 75.2 years, mean age 37.6 years); and in (c) eight prepubertal patients with growth hormone (GH) deficiency (aged 4.2 to 13.5 years, mean age 8.9 years). Boys had higher median values for SSR than girls (pre-pubertal children: 92.7 vs 64.5 mg 30 min-1 pubertal children: 110.3 vs 73.1 mg 30 min-1), and men showed higher values than women (135.5 vs 49.2 mg 30 min-1). In addition, the change in sweat excretion rate from childhood to adulthood showed a difference between the sexes. Both pre-pubertal and pubertal boys had a lower secretion value than adult men (p less than 0.001 and 0.01, respectively), whereas girls showed higher secretion values than adult women (p less than 0.01 and p less than 0.001, respectively). There was a significant increase in SSR from prepuberty to puberty (p less than 0.001) for both sexes. The children with GH deficiency, all pre-pubertal, showed significantly reduced SSR (p less than 0.001) compared with the healthy children (median values: 32.8 vs 80.0 mg 30 min-1). We conclude that (a) sweat secretion pattern in children shows a significant sex difference and (b) sweating in children is dependent on growth hormone.


Subject(s)
Growth Hormone/deficiency , Sweating , Adolescent , Adult , Age Factors , Aged , Child , Female , Humans , Male , Middle Aged , Puberty/physiology , Sex Factors
15.
Diabetologia ; 33(9): 561-8, 1990 Sep.
Article in English | MEDLINE | ID: mdl-2253834

ABSTRACT

The differential diagnosis between Type 1 (insulin-dependent) and Type 2 (non-insulin-dependent) diabetes is complicated since no specific markers are available for either disease. In this study, 244 consecutive patients were diagnosed with diabetes mellitus during two years in Malmö (230,000 inhabitants), corresponding to an incidence rate of 53.100,000(-1).year-1. Age, body mass index, HbA1c, C-peptide, and levels of islet cell antibodies were determined at the clinical onset, and related to the classification at diagnosis and at follow-up (n = 233) after a median time of 31 (range 1-49) months. After diagnosis, 42 of 244 (17%) were started on insulin while 202 of 244 (83%) were not. Islet cell antibodies were present in 25 of 42 (60%), and in 18 of 183 (10%), respectively. In the non-insulin treated group, patients with islet cell antibodies had lower body mass index (p less than 0.001), higher HbA1c (p less than 0.004), and lower C-peptide (p less than 0.001) than patients without. At follow-up, 11 of 18 (61%) islet cell positive patients were changed to insulin treatment, as were six other patients. Insulin was discontinued in five initially insulin-treated but islet cell antibody negative patients. The sensitivity, specificity and predictive value for insulin treatment at follow-up were for islet cell antibody positivity; 72%, 96% and 84%, respectively, and for low C-peptide value; 60%, 96%, and 80%, respectively. Islet cell antibodies and low C-peptide at diagnosis of diabetes mellitus are concluded to be useful markers to predict insulin dependence.


Subject(s)
Autoantibodies/analysis , Biomarkers/blood , C-Peptide/blood , Diabetes Mellitus/blood , Insulin/therapeutic use , Adolescent , Adult , Age Factors , Aged , Child , Diabetes Mellitus/diagnosis , Diabetes Mellitus/drug therapy , Diet, Diabetic , Fasting , Female , Follow-Up Studies , Glycated Hemoglobin/analysis , Humans , Hypoglycemic Agents/therapeutic use , Islets of Langerhans/immunology , Male , Middle Aged , Prognosis , Sweden
17.
Diabetes ; 37(3): 347-50, 1988 Mar.
Article in English | MEDLINE | ID: mdl-2453387

ABSTRACT

Neonatal insulin-dependent diabetes mellitus (IDDM) occurs rarely. A sibship of two HLA-Dw3/4-positive boys who developed IDDM within the 1st wk of life is described. Although the HLA-D region genotype would be consistent with IDDM associated with islet autoimmunity, islet cell antibodies were negative, but both boys exhibited the presence of a novel autoantibody that reacted specifically with a conspicuous, yet unidentified, determinant in the interstitial tissue among the acinar cells. The possible relationship between this acinar nonislet autoantibody and permanent neonatal diabetes remains to be established.


Subject(s)
Autoantibodies/analysis , Diabetes Mellitus, Type 1/genetics , HLA-D Antigens/analysis , Pancreas/immunology , Diabetes Mellitus, Type 1/immunology , Epitopes/analysis , Extracellular Matrix/immunology , Fluorescent Antibody Technique , Humans , Infant, Newborn , Male , Pedigree
18.
Acta Paediatr Scand Suppl ; 347: 176-9, 1988.
Article in English | MEDLINE | ID: mdl-3254032

ABSTRACT

A total of 23 previously untreated and 28 previously treated GH deficient children were included for at least 12 months in a trial of recombinant somatropin, 0.1 IU/kg/day given by subcutaneous injection. All the children increased their height velocity over the pretreatment values, to nearly 11 cm/year, corresponding to a significant increase in height of 1 SD score for chronological age. The increase in height SD score for bone age was also statistically significant. No adverse effects were recorded, though one child experienced local itching and redness at the injection site which did not recur after a short cessation of therapy. One child developed detectable antibodies to recombinant somatropin, but the binding capacity was low and no clinical symptoms or growth attenuation occurred. Recombinant somatropin was shown to be safe and effective during the first year of therapy in children with GH deficiency.


Subject(s)
Growth Hormone/therapeutic use , Adolescent , Antibody Formation , Body Height/drug effects , Child , Child, Preschool , Female , Finland , Growth Hormone/adverse effects , Growth Hormone/deficiency , Growth Hormone/immunology , Humans , Male , Recombinant Proteins , Sweden
19.
Acta Paediatr Scand ; 76(4): 608-11, 1987 Jul.
Article in English | MEDLINE | ID: mdl-3630678

ABSTRACT

The 24-hour urinary excretion of C-peptide and the plasma C-peptide concentration were measured at the onset of insulin dependent diabetes mellitus (IDDM) in children. The excretion of C-peptide was twice as high as that found in normal control subjects, whereas the plasma C-peptide values were markedly lower, indicating increased urinary leakage of C-peptide in this phase of the disease. In the diabetic children under seven years of age the mean value of C-peptide excretion was clearly lower than in the older children.


Subject(s)
C-Peptide/urine , Diabetes Mellitus, Type 1/urine , Adolescent , Age Factors , Child , Child, Preschool , Circadian Rhythm , Female , Humans , Male
20.
Neuropediatrics ; 18(1): 57-8, 1987 Feb.
Article in English | MEDLINE | ID: mdl-3561709

ABSTRACT

Meningoencephalitis associated with serological evidence of Mycoplasma pneumoniae infection is reported in two children, aged 11 and 12. In both cases the neurological illness started with an attack of generalised convulsions, followed by changes in the electroencephalogram, which lasted up to 5 wks. Both children recovered completely without signs of sequelae. Attention is drawn to the wide spectrum of neurological complications which can be associated with this infection.


Subject(s)
Meningoencephalitis/etiology , Pneumonia, Mycoplasma/complications , Seizures/etiology , Child , Electroencephalography , Female , Humans , Male
SELECTION OF CITATIONS
SEARCH DETAIL
...